{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:52:39Z","timestamp":1793141559237,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Desensitization strategies for highly sensitized kidney transplant candidates remain limited in efficacy. Tocilizumab, an interleukin-6 receptor antagonist, has been proposed as an adjunct to IVIg to reduce HLA antibody burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>In this prospective controlled cohort study, highly sensitized candidates (median calculated panel reactive antibody [cPRA], 98.0%) were (n\u2005=\u200519) or were not (n\u2005=\u200515) treated with tocilizumab and IVIg. All tocilizumab-treated patients had failed \u22653 mo of IVIg-based desensitization. We assessed changes in cPRA, unacceptable antigens (U\/As), transplant rates, and posttransplant outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Tocilizumab-treated patients were more likely to demonstrate any reduction in cPRA during the study period (84.2% versus 33.3%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.002). Median cPRA change at nadir was \u20130.9% versus 0.0% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02), although end-of-study differences were not statistically significant. Treated patients more frequently achieved removal of high-impact U\/As (median cPRA of removed U\/As 31.7% versus 0.0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.004), and 3 underwent transplantation across antigens previously listed as unacceptable. Transplant rates (89.5% versus 73.3%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.4) and early posttransplant outcomes\u2014including rejection, graft loss, BK viremia, renal function, de novo donor-specific antibody, and donor-specific antibody rebound\u2014were similar between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>In this controlled cohort, tocilizumab combined with IVIg was associated with greater reductions in HLA antibody burden without an apparent increase in early posttransplant immunologic risk. These findings support further evaluation of interleukin-6 (IL-6) blockade as an adjunctive desensitization strategy, particularly in candidates with limited transplant access despite high allocation priority.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005829","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:27:20Z","timestamp":1782858440000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Desensitization With Tocilizumab and IVIg: A Prospective Controlled Cohort Study in a Predominantly Black American Population"],"prefix":"10.1097","author":[{"given":"Carly J.","family":"Amato","sequence":"first","affiliation":[{"name":"Division of Transplant Surgery, Histocompatibility and Immunogenetics Laboratory, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Seelam","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Carmelle","family":"Philogene","sequence":"additional","affiliation":[{"name":"Division of Transplant Surgery, Histocompatibility and Immunogenetics Laboratory, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Paulus","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Moinuddin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"R1-20260630","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-20260630","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1034\/j.1600-6143.2002.20809.x","article-title":"Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg).","volume":"2","author":"Glotz","year":"2002","journal-title":"Am J Transplant"},{"key":"R3-20260630","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00007890-199402270-00014","article-title":"Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.","volume":"57","author":"Tyan","year":"1994","journal-title":"Transplantation"},{"key":"R4-20260630","doi-asserted-by":"crossref","first-page":"694763","DOI":"10.3389\/fimmu.2021.694763","article-title":"Emerging new approaches in desensitization: targeted therapies for HLA sensitization.","volume":"12","author":"Choi","year":"2021","journal-title":"Front Immunol"},{"key":"R5-20260630","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ki.2014.261","article-title":"A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.","volume":"87","author":"Jackson","year":"2015","journal-title":"Kidney Int"},{"key":"R6-20260630","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival.","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"R7-20260630","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ajt.15889","article-title":"Plasma cell targeting to prevent antibody-mediated rejection.","volume":"20","author":"Woodle","year":"2020","journal-title":"Am J Transplant"},{"key":"R8-20260630","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/ajt.15149","article-title":"The national landscape of deceased donor kidney transplantation for the highly sensitized: transplant rates, waitlist mortality, and posttransplant survival under KAS.","volume":"19","author":"Jackson","year":"2019","journal-title":"Am J Transplant"},{"key":"R9-20260630","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/ajt.13770","article-title":"Changes in deceased donor kidney transplantation one year after KAS implementation.","volume":"16","author":"Stewart","year":"2016","journal-title":"Am J Transplant"},{"key":"R10-20260630","doi-asserted-by":"crossref","first-page":"e13751","DOI":"10.1111\/ctr.13751","article-title":"Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: is there still a role for desensitization?","volume":"33","author":"Schinstock","year":"2019","journal-title":"Clin Transplant"},{"key":"R11-20260630","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.humimm.2016.11.004","article-title":"Casting a smaller net into a bigger donor pool: a single center\u2019s experience with the new kidney allocation system.","volume":"78","author":"Houp","year":"2017","journal-title":"Hum Immunol"},{"key":"R12-20260630","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6.","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R13-20260630","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/TP.0000000000000437","article-title":"Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization.","volume":"98","author":"Kim","year":"2014","journal-title":"Transplantation"},{"key":"R14-20260630","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13063-024-08020-0","article-title":"Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).","volume":"25","author":"Streichart","year":"2024","journal-title":"Trials"},{"key":"R15-20260630","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients.","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"R16-20260630","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/TXD.0000000000001139","article-title":"Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates.","volume":"7","author":"Daligault","year":"2021","journal-title":"Transplant Direct"},{"key":"R17-20260630","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients.","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"R18-20260630","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R19-20260630","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","article-title":"The effect of desensitization protocols on human splenic B-cell populations in vivo.","volume":"7","author":"Ramos","year":"2007","journal-title":"Am J Transplant"},{"key":"R20-20260630","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/jcm12020424","article-title":"Tocilizumab evaluation in HLA-desensitization before kidney transplantation as an add-on therapy to apheresis: the TETRA study.","volume":"12","author":"Jouve","year":"2023","journal-title":"J Clin Med"},{"key":"R21-20260630","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humimm.2017.10.020","article-title":"Rapid optimized flow cytometric crossmatch (FCXM) assays: the Halifax and Halifaster protocols.","volume":"79","author":"Liwski","year":"2018","journal-title":"Hum Immunol"},{"key":"R22-20260630","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/TP.0000000000003838","article-title":"Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies.","volume":"106","author":"Gupta","year":"2022","journal-title":"Transplantation"},{"key":"R23-20260630","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000004624","article-title":"The molecular phenotype of kidney transplants: insights from the MMDx project.","volume":"108","author":"Halloran","year":"2024","journal-title":"Transplantation"},{"key":"R24-20260630","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 kidney meeting report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.","volume":"24","author":"Naesens","year":"2024","journal-title":"Am J Transplant"},{"key":"R25-20260630","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/01.TP.0000090868.88895.E0","article-title":"Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients.","volume":"76","author":"Zachary","year":"2003","journal-title":"Transplantation"},{"key":"R26-20260630","first-page":"229","article-title":"Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection.","author":"Kannabhiran","year":"2012","journal-title":"Clin Transpl"},{"key":"R27-20260630","doi-asserted-by":"crossref","first-page":"e1695","DOI":"10.1097\/TXD.0000000000001695","article-title":"Anti-HLA class II antibodies are the most resistant to desensitization in crossmatch-positive living-donor kidney transplantations: a patient series.","volume":"10","author":"de Weerd","year":"2024","journal-title":"Transplant Direct"},{"key":"R28-20260630","doi-asserted-by":"crossref","first-page":"180","DOI":"10.6002\/ect.2021.0334","article-title":"T-cell-positive, B-cell-negative flow cytometry crossmatch: frequency, HLA locus specificity, and mechanisms among 3073 clinical flow cytometry crossmatch tests.","volume":"20","author":"Putheti","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"R29-20260630","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"key":"R30-20260630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/jcm11010091","article-title":"Tocilizumab trough levels variability in kidney-transplant candidates undergoing desensitization.","volume":"11","author":"Truffot","year":"2021","journal-title":"J Clin Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:27:23Z","timestamp":1782858443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005829","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}